| GTO ID | GTC0267 |
| Trial ID | NCT02556736 |
| Disease | Retinitis Pigmentosa |
| Altered gene | ChR2 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | RST-001 |
| Phase | Phase1|Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP) |
| Year | 2015 |
| Country | United States |
| Company sponsor | AbbVie |
| Other ID(s) | RST-001-CP-0001 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||||
|
|||||||||||